within Pharmacolibrary.Drugs.ATC.C;

model C03CA01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.0001,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600,            
    Vdp             = 0.004,
    k12             = 4,
    k21             = 4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C03CA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Furosemide is a potent loop diuretic used primarily to treat edema associated with congestive heart failure, liver cirrhosis, and renal disease, as well as hypertension. It is approved for use and remains a mainstay in acute and chronic treatment of fluid overload.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following a single oral dose.</p><h4>References</h4><ol><li><p>Sleeper, MM, et al., &amp; Papich, MG (2019). Pharmacokinetics of furosemide after intravenous, oral and transdermal administration to cats. <i>Journal of feline medicine and surgery</i> 21(10) 882–886. DOI:<a href=\"https://doi.org/10.1177/1098612X18805879\">10.1177/1098612X18805879</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30339054/\">https://pubmed.ncbi.nlm.nih.gov/30339054</a></p></li><li><p>Ponto, LL, &amp; Schoenwald, RD (1990). Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I). <i>Clinical pharmacokinetics</i> 18(5) 381–408. DOI:<a href=\"https://doi.org/10.2165/00003088-199018050-00004\">10.2165/00003088-199018050-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2185908/\">https://pubmed.ncbi.nlm.nih.gov/2185908</a></p></li><li><p>Felker, GM, et al., &amp; O&#x27;Connor, CM (2011). Diuretic strategies in patients with acute decompensated heart failure. <i>The New England journal of medicine</i> 364(9) 797–805. DOI:<a href=\"https://doi.org/10.1056/NEJMoa1005419\">10.1056/NEJMoa1005419</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21366472/\">https://pubmed.ncbi.nlm.nih.gov/21366472</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C03CA01;
